Literature DB >> 1709809

Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate.

C K Tan1, R Civil, A M Mian, A G So, K M Downey.   

Abstract

The effects of AZTMP and other nucleoside 5'-monophosphates on the RNA-dependent DNA polymerase and RNase H activities of a recombinant HIV reverse transcriptase have been investigated. Both activities are sensitive to inhibition by millimolar concentrations of AZTMP with MgCl2 as divalent cation activator. Substitution of Mn2+ for Mg2+ markedly potentiates the inhibition of RNase H activity by AZTMP, reducing the IC50 from 5 to 0.05 mM. In contrast, Mn2+ does not alter the sensitivity of the RNA-dependent DNA polymerase activity to inhibition by AZTMP. The inhibition of RNase H activity by AZTMP can be reversed by increasing concentrations of the substrate poly(A)/poly(dT), suggesting that AZTMP may compete with the substrate for binding at the active site of RNase H. Other nucleoside 5'-monophosphates do not inhibit RNase H in the presence of Mg2+. However, in the presence of Mn2+, deoxy- and dideoxynucleoside 5'-monophosphates that are complementary to the DNA strand of the heteroduplex substrate are somewhat inhibitory. The RNA-dependent DNA polymerase activity is a slightly inhibited by AZTMP and ddTMP in either Mg2+ or Mn2+, and substitution of Mn2+ for Mg2+ results in inhibition by ddAMP as well. Naturally occurring ribo- or deoxyribonucleoside 5'-monophosphates are not inhibitory at concentrations up to 5 mM. Since AZTTP inhibits the RNA-dependent DNA polymerase activity of HIV reverse transcriptase at nanomolar concentrations, it is unlikely that the inhibition of this activity by AZTMP plays a significant role in the antiviral effect of AZT. However, the inhibition of the RNase H activity by AZTMP, which can reach millimolar concentrations in vivo, may account for part of the sensitivity of the virus to AZT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709809     DOI: 10.1021/bi00234a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

Review 1.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

Authors:  Galina N Nikolenko; Sarah Palmer; Frank Maldarelli; John W Mellors; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 4.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Synthesis of nucleoside 5'-O-alpha,beta-methylene-beta-triphosphates and evaluation of their potency towards inhibition of HIV-1 reverse transcriptase.

Authors:  Y Ahmadibeni; C Dash; M J Hanley; S F J Le Grice; H K Agarwal; K Parang
Journal:  Org Biomol Chem       Date:  2010-01-13       Impact factor: 3.876

Review 6.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

7.  The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H.

Authors:  I W Althaus; K M Franks; K B Langley; F J Kézdy; T Peterson; S E Buxser; D E Decker; L A Dolak; R G Ulrich; F Reusser
Journal:  Experientia       Date:  1996-04-15

Review 8.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

9.  Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies.

Authors:  Anthony K Felts; Krystal Labarge; Joseph D Bauman; Dishaben V Patel; Daniel M Himmel; Eddy Arnold; Michael A Parniak; Ronald M Levy
Journal:  J Chem Inf Model       Date:  2011-07-26       Impact factor: 4.956

Review 10.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.